


Irsonontrine maleate

Cat. No.:	HY-132821A
CAS No.:	1630083-70-3
Molecular Formula:	C ₂₆ H ₂₆ N ₄ O ₇
Molecular Weight:	506.51
Target:	Phosphodiesterase (PDE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Irsonontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsonontrine maleate can be used for the research of neurological diseases ^{[1][2]} .
IC₅₀ & Target	PDE9 ^[1]
In Vivo	<p>Irsonontrine (0.3, 3.3 mg/kg; p.o.) maleate exhibits a significant ameliorative effect on the percentage of exploration of the novel object at 3.3 mg/kg in Scopolamine-induced rats^[1].</p> <p>Irsonontrine (1 mg/kg; p.o.) maleate and memantine hydrochloride (1 mg/kg; p.o.) combined treatment group exhibits a significantly higher percentage of exploration of the novel object than memantine hydrochloride (1 mg/kg) alone^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1
- [2]. Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. *Drugs Aging*. 2019;36(4):309-319.
- [3]. Eisai to present latest research on Alzheimer's disease / dementia pipeline at the 14th international conference on Alzheimer's & Parkinson's diseases

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA